Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers

Publication Date: December 15, 2022

Treatment

Recommendation 1.1

Programmed death-ligand 1 (PD-L1) immunohistochemistry testing should be performed in patients with recurrent HNSCC. (EB, B, H, S)
1048203

Recommendation 1.2

PD-L1 combined positive score (CPS) ≥1 should be interpreted as positive and correlates with a clinical benefit to PD-1 inhibitors. (EB, B, H, S)
1048203

Recommendation 1.3

Tumor mutational burden (TMB) testing may be performed in patients with recurrent or metastatic HNSCC when CPS is not available or in patients with rare tumors. (EB, B, H, S)
1048203

Recommendation 1.4

TMB ≥10 should be interpreted as high and correlates with a clinical benefit to PD-1 inhibitors. (EB, B, H, S)
1048203

Recommendation 2.1

Pembrolizumab monotherapy or pembrolizumab, platinum, and 5-fluorouracil (5-FU) should be offered as first-line treatment for patients with recurrent or metastatic HNSCC with a CPS ≥1. (EB, B, H, S)
1048203

Recommendation 2.2

Pembrolizumab, platinum, and 5-FU may be offered as first-line treatment for patients with recurrent or metastatic HNSCC with a CPS <1. (EB, B, M, S)
1048203

Recommendation 3.1

Pembrolizumab or nivolumab should be offered to patients with platinum-refractory recurrent or metastatic HNSCC, regardless of CPS status. (EB, B, H, S)
1048203

Recommendation 4.1

Toripalimab, camrelizumab or tislelizumab, with gemcitabine and cisplatin, should be offered as first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer. (EB, B, H, S)
Qualifying statement: Pembrolizumab or nivolumab may be offered with gemcitabine and cisplatin if the immune checkpoint inhibitors in Recommendation 4.1 are unavailable.
1048203

Recommendation 4.2

Programmed cell death protein 1 (PD-1) inhibitors may be offered to patients with recurrent or metastatic nasopharyngeal cancer who have progressed following platinum-based therapy. (IC, B, L, W)
1048203

Recommendation 5.1

For patients with oligometastatic HNSCC, radiation therapy is safe to give concurrently with immunotherapy for the purpose of palliation or local control, but should not be given to enhance response to immunotherapy outside of a clinical trial. (EB, , M, W)
1048203

Recommendation 6.1

Pembrolizumab may be offered to patients with TMB-high recurrent or metastatic rare head and neck cancers. (EB, B, M, W)
1048203

Recommendation 6.2

Pembrolizumab may be offered to patients with PD-L1 positive recurrent or metastatic salivary gland cancer. (EB, B, M, W)
1048203

Recommendation Grading

Disclaimer

The information in this patient summary should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.

Overview

Title

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers

Authoring Organization

Publication Month/Year

December 15, 2022

Document Type

Guideline

Country of Publication

US

Inclusion Criteria

Male, Female, Adult, Older adult

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Assessment and screening, Treatment

Diseases/Conditions (MeSH)

D007167 - Immunotherapy, D006258 - Head and Neck Neoplasms, D000082082 - Immune Checkpoint Inhibitors

Keywords

immunotherapy, head and neck cancer, Cancer immunotherapy, PD-L1, biomarker, immune-checkpoint inhibitor

Source Citation

Yilmaz E, Ismaila N, Bauman J, et al. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. J Clin Oncol. 2022 Dec 15. doi: 10.1200/JCO.22.02328

Supplemental Methodology Resources

Data Supplement, Evidence Tables

Methodology

Number of Source Documents
86
Literature Search Start Date
January 1, 2000
Literature Search End Date
February 1, 2022